Trending...
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- Holiday Decorations Most Likely to Cause Injuries
Genprex Stock Symbol: GNPX is Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes
AUSTIN, Texas - WisconsinEagle -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Wisconsin Eagle
Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024.
The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024.
The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value.
Presentations to Highlight Gene Therapies for Cancer and Diabetes
More on Wisconsin Eagle
GNPX has announced its participation in the following upcoming investor and industry conferences:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
To watch the video, visit the GNPX website at: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Wisconsin Eagle
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024.
The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024.
The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value.
Presentations to Highlight Gene Therapies for Cancer and Diabetes
More on Wisconsin Eagle
- When The Call Hits Home - Heartfelt Holiday Episode Focusing on First Responders and Family Wellness
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
GNPX has announced its participation in the following upcoming investor and industry conferences:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
To watch the video, visit the GNPX website at: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on Wisconsin Eagle
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California